Orphan Drugs and Orphan Drug Policies in Selected Countries

Park, Sylvia

Full metadata record

DC Field	Value
dc.contributor.author	Park, Sylvia
dc.date.accessioned	2017-06-02T05:09:13Z
dc.date.available	2017-06-02T05:09:13Z
dc.date.issued	2015-09-30
dc.identifier.uri	https://repository.kihasa.re.kr/handle/201002/21443
dc.description.abstract	An orphan drug is a pharmaceutical product that is developed to diagnose, prevent or treat a rare disease afflicting a very small fraction of the population. A rare disease is defined as a medical condition affecting not more than 20,000 people in Korea, fewer than 200,000 people in the United States, not more than 50,000 in Japan, and not more than 5 in 10,000 people in the EU region. One of the prominent characteristics of these rare diseases is that some 80 percent of them, most of which are life-threatening or chronically debilitating, are of genetic origin. There are more than 6,000 rare diseases known today, with to the tune of 100 million affected by one or more of them in the OECD countries. ("Patients' Needs, Medicines Innovation and the Global Public Interests", 2014, UCL School of Pharmacy Drugs) As they are for a small number of patients with gravely serious medical conditions that have few, if any, alternative treatments, orphan drugs tend to be very expensive.
dc.format	text/plain
dc.format.extent	5
dc.language	eng
dc.publisher	한국보건사회연구원
dc.publisher	Korea Institute for Health and Social Affairs
dc.rights	Attribution-NonCommercial-NoDerivs 2.0 Korea
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/2.0/kr/
dc.title	Orphan Drugs and Orphan Drug Policies in Selected Countries
dc.type	Article
dc.type.local	Article(Series)
dc.contributor.alternativeName	박실비아
dc.contributor.affiliatedAuthor	박실비아
dc.citation.title	Research in Brief
dc.citation.number	10
dc.citation.startPage	1
dc.citation.endPage	5
dc.identifier.bibliographicCitation	Research in Brief, no. 10, pp. 1 - 5